HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States

Abstract Background Human papillomavirus (HPV) infection can cause various cancers and can be prevented through vaccination. The American Cancer Society (ACS) has set an HPV vaccination completion target in 13-year-old children to 80% by 2026. While HPV vaccine coverage (proportion ever vaccinated)...

Full description

Bibliographic Details
Main Authors: Vimalanand S. Prabhu, Neha Bansal, Zhiwen Liu, Rodney Finalle, Martin Sénécal, Smita Kothari, Kemar Trowers, Evan Myers
Format: Article
Language:English
Published: BMC 2021-09-01
Series:BMC Public Health
Subjects:
Online Access:https://doi.org/10.1186/s12889-021-11664-1
id doaj-a37ba04ef0e04c949d9a1f1f632122df
record_format Article
spelling doaj-a37ba04ef0e04c949d9a1f1f632122df2021-09-12T11:15:00ZengBMCBMC Public Health1471-24582021-09-012111910.1186/s12889-021-11664-1HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United StatesVimalanand S. Prabhu0Neha Bansal1Zhiwen Liu2Rodney Finalle3Martin Sénécal4Smita Kothari5Kemar Trowers6Evan Myers7Center for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncComplete HEOR Solutions (CHEORS)Center for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncCenter for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncComplete HEOR Solutions (CHEORS)Center for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncCenter for Observational and Real-World Evidence, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncDivision of Women’s Community and Population Health, Department of Obstetrics & Gynaecology, Duke University Medical CenterAbstract Background Human papillomavirus (HPV) infection can cause various cancers and can be prevented through vaccination. The American Cancer Society (ACS) has set an HPV vaccination completion target in 13-year-old children to 80% by 2026. While HPV vaccine coverage (proportion ever vaccinated) estimates are available, annual uptakes (proportion initiating vaccine in a year) in the United States (U.S.) are not well-known. Methods We analyzed MarketScan® claims database to assess HPV vaccination uptakes in the U.S. among the 9- to 26-year-olds in 2006–2016. The annual uptake was the ratio of the number of enrollees who had a first record of an HPV vaccine during the year, and the number of enrollees of similar age and sex that year. Results Uptake was below 1% among children turning 9 and 10 years old during the year. Since 2009 among female and since 2013 among males, the annual uptake has been the highest in those turning 13 years old (19.7% among females and 17.6% among males in 2016). Catch-up vaccination among older adolescents and young adults increased after Advisory Committee for Immunization Practices (ACIP) recommendations, but eventually slowed down as more younger persons were vaccinated. Most young adolescents were vaccinated by pediatricians, whereas young adult women were predominantly vaccinated by obstetricians/gynecologists and young adult males by family physicians. While only about half of the adolescents had well-check visits, the majority of those who initiated HPV vaccination had one the same year. Conclusion Continued increase in uptake is needed to reach the ACS 2026 goals.https://doi.org/10.1186/s12889-021-11664-1Human papillomavirusHPV vaccineVaccination uptakeTemporal trendsSex differencesInsurance claims data
collection DOAJ
language English
format Article
sources DOAJ
author Vimalanand S. Prabhu
Neha Bansal
Zhiwen Liu
Rodney Finalle
Martin Sénécal
Smita Kothari
Kemar Trowers
Evan Myers
spellingShingle Vimalanand S. Prabhu
Neha Bansal
Zhiwen Liu
Rodney Finalle
Martin Sénécal
Smita Kothari
Kemar Trowers
Evan Myers
HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
BMC Public Health
Human papillomavirus
HPV vaccine
Vaccination uptake
Temporal trends
Sex differences
Insurance claims data
author_facet Vimalanand S. Prabhu
Neha Bansal
Zhiwen Liu
Rodney Finalle
Martin Sénécal
Smita Kothari
Kemar Trowers
Evan Myers
author_sort Vimalanand S. Prabhu
title HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
title_short HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
title_full HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
title_fullStr HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
title_full_unstemmed HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
title_sort hpv vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the united states
publisher BMC
series BMC Public Health
issn 1471-2458
publishDate 2021-09-01
description Abstract Background Human papillomavirus (HPV) infection can cause various cancers and can be prevented through vaccination. The American Cancer Society (ACS) has set an HPV vaccination completion target in 13-year-old children to 80% by 2026. While HPV vaccine coverage (proportion ever vaccinated) estimates are available, annual uptakes (proportion initiating vaccine in a year) in the United States (U.S.) are not well-known. Methods We analyzed MarketScan® claims database to assess HPV vaccination uptakes in the U.S. among the 9- to 26-year-olds in 2006–2016. The annual uptake was the ratio of the number of enrollees who had a first record of an HPV vaccine during the year, and the number of enrollees of similar age and sex that year. Results Uptake was below 1% among children turning 9 and 10 years old during the year. Since 2009 among female and since 2013 among males, the annual uptake has been the highest in those turning 13 years old (19.7% among females and 17.6% among males in 2016). Catch-up vaccination among older adolescents and young adults increased after Advisory Committee for Immunization Practices (ACIP) recommendations, but eventually slowed down as more younger persons were vaccinated. Most young adolescents were vaccinated by pediatricians, whereas young adult women were predominantly vaccinated by obstetricians/gynecologists and young adult males by family physicians. While only about half of the adolescents had well-check visits, the majority of those who initiated HPV vaccination had one the same year. Conclusion Continued increase in uptake is needed to reach the ACS 2026 goals.
topic Human papillomavirus
HPV vaccine
Vaccination uptake
Temporal trends
Sex differences
Insurance claims data
url https://doi.org/10.1186/s12889-021-11664-1
work_keys_str_mv AT vimalanandsprabhu hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates
AT nehabansal hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates
AT zhiwenliu hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates
AT rodneyfinalle hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates
AT martinsenecal hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates
AT smitakothari hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates
AT kemartrowers hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates
AT evanmyers hpvvaccinationuptakeandadministrationfrom2006to2016inacommerciallyinsuredpopulationoftheunitedstates
_version_ 1717755844954685440